{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:52Z","timestamp":1793316292916,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University Hospital Basel, Switzerland"},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.biopsych.2014.11.015","type":"journal-article","created":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T21:47:32Z","timestamp":1417297652000},"page":"544-553","source":"Crossref","is-referenced-by-count":377,"title":["Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects"],"prefix":"10.1016","volume":"78","author":[{"given":"Yasmin","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Enzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Grouzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin H.","family":"Preller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz X.","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Brenneisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Borgwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2014.11.015_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: A review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.biopsych.2014.11.015_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2014.11.015_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","article-title":"How LSD originated","volume":"11","author":"Hofmann","year":"1979","journal-title":"J Psychedelic Drugs"},{"key":"10.1016\/j.biopsych.2014.11.015_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM195801022580106","article-title":"The pharmacology of mescaline and D-lysergic acid diethylamide (LSD)","volume":"258","author":"Koelle","year":"1958","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2014.11.015_bib5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/archneurpsyc.1956.02330240026003","article-title":"Model psychoses induced by LSD-25 in normals. I. Psychophysiological investigations, with special reference to the mechanism of the paranoid reaction","volume":"75","author":"Bercel","year":"1956","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for narcotic addict: A controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib8","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"Grof","year":"1973","journal-title":"Int Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib10","first-page":"144","article-title":"LSD-assisted psychotherapy with terminal cancer patients","volume":"9","author":"Pahnke","year":"1969","journal-title":"Curr Psychiatr Ther"},{"key":"10.1016\/j.biopsych.2014.11.015_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.biopsych.2014.11.015_bib12","unstructured":"European Monitoring Center for Drugs and Drug Addiction. European drug report 2014. Available at: www.emcdda.europa.eu. Accessed August 13, 2014."},{"key":"10.1016\/j.biopsych.2014.11.015_bib13","unstructured":"Johnston LD, O Malley PM, Bachmann JG, Schulenberg JE, Miech RA (2014): Monitoring the Future: National Survey Results on Drug Use, 1975-2013: Volume 2, College Students and Adults Ages 19-55. Ann Arbor: Institute for Social Research, University of Michigan"},{"key":"10.1016\/j.biopsych.2014.11.015_bib14","doi-asserted-by":"crossref","unstructured":"Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2014): LSD enhances suggestibility in healthy volunteers. Psychopharmacology. http:\/\/dx.doi\/10.1007\/s00213-014-3714-z","DOI":"10.1007\/s00213-014-3714-z"},{"key":"10.1016\/j.biopsych.2014.11.015_bib15","first-page":"279","article-title":"Lysergs\u00e4ure\u00e4thylamid, ein Phantastikum aus der Mutterkorngruppe","volume":"60","author":"Stoll","year":"1947","journal-title":"Schweiz Arch Neurol Psychiatr"},{"key":"10.1016\/j.biopsych.2014.11.015_bib16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1749-6632.1957.tb40756.x","article-title":"Lysergic acid diethylamide and related substances","volume":"66","author":"Rothlin","year":"1957","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2014.11.015_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archneurpsyc.1956.02330250052007","article-title":"Progression of effects of lysergic acid diethylamide (LSD)","volume":"76","author":"Salvatore","year":"1956","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0010-440X(62)80024-8","article-title":"Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures","volume":"3","author":"Hollister","year":"1962","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00213-002-1237-5","article-title":"Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively","volume":"165","author":"Riba","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/JCP.0b013e31823607f6","article-title":"Autonomic, neuroendocrine, and immunological effects of ayahuasca: A comparative study with d-amphetamine","volume":"31","author":"Dos Santos","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2005-916185","article-title":"Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers","volume":"38","author":"Gouzoulis-Mayfrank","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","article-title":"Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib25","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2014.11.015_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1126\/science.345.6192.18","article-title":"High hopes","volume":"345","author":"Kupferschmidt","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2014.11.015_bib29","doi-asserted-by":"crossref","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2014.11.015_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S1461145713001132","article-title":"Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination","volume":"17","author":"Hysek","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt1971122part1245","article-title":"Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man","volume":"12","author":"Martin","year":"1971","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2014.11.015_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02584089","article-title":"The Addiction Research Center Inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine","volume":"4","author":"Hill","year":"1963","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.biopsych.2014.11.015_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0924-9338(99)80686-5","article-title":"Hallucinogenic drug induced states resemble acute endogenous psychoses: Results of an empirical study","volume":"13","author":"Gouzoulis-Mayfrank","year":"1998","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: Contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2014.11.015_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00005053-196808000-00008","article-title":"Lysergic acid diethylamide (LSD-25) and schizophrenic reactions: A comparative study","volume":"147","author":"Langs","year":"1968","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.biopsych.2014.11.015_bib36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/archpsyc.1992.01820030038005","article-title":"Gating and habituation of the startle reflex in schizophrenic patients","volume":"49","author":"Braff","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.57.6.609","article-title":"Prepulse inhibition of the startle response in men with schizophreni: Effects of age of onset of illness, symptoms, and medication","volume":"57","author":"Kumari","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0006-3223(02)01925-X","article-title":"Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia","volume":"54","author":"Ludewig","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib39","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.biopsych.2008.04.019","article-title":"Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia","volume":"64","author":"Quednow","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00213-009-1718-x","article-title":"LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor","volume":"208","author":"Halberstadt","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.pnpbp.2010.02.008","article-title":"Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition","volume":"34","author":"Palenicek","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0893-133X(01)00282-2","article-title":"Effect of LSD on prepulse inhibition and spontaneous behavior in the rat: A pharmacological analysis and comparison between two rat strains","volume":"25","author":"Ouagazzal","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0006-8993(97)00316-8","article-title":"DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum","volume":"761","author":"Sipes","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2014.11.015_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02246437","article-title":"Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs","volume":"122","author":"Varty","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00213-006-0566-1","article-title":"The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats","volume":"189","author":"Krebs-Thomson","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib46","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1017\/S1461145713000722","article-title":"Serotonergic hallucinogens as translational models relevant to schizophrenia","volume":"16","author":"Halberstadt","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"suppl 2","key":"10.1016\/j.biopsych.2014.11.015_bib48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-2007-979356","article-title":"Methodological issues of human experimental research with hallucinogens","volume":"31","author":"Gouzoulis-Mayfrank","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"suppl 2","key":"10.1016\/j.biopsych.2014.11.015_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib50","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.107.129056","article-title":"Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics","volume":"323","author":"Farre","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2014.11.015_bib51","article-title":"Die Eigenschaftsw\u00f6rterliste","author":"Janke","year":"1978","journal-title":"G\u00f6ttingen: Hogrefe"},{"key":"10.1016\/j.biopsych.2014.11.015_bib52","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek","year":"2014","journal-title":"Soc Cogn Affect Neurosci"},{"key":"10.1016\/j.biopsych.2014.11.015_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0893-133X(95)00136-2","article-title":"The psychopharmacology of hallucinogens","volume":"14","author":"Abraham","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib54","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.biopsych.2014.11.015_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib56","first-page":"46","article-title":"Mescaline: The chemistry and pharmacology of its analogs","volume":"36","author":"Shulgin","year":"1973","journal-title":"Lloydia"},{"key":"10.1016\/j.biopsych.2014.11.015_bib57","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2014.11.015_bib58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00213-012-2645-9","article-title":"MDMA enhances \u201cmind reading\u201d of positive emotions and impairs \u201cmind reading\u201d of negative emotions","volume":"222","author":"Hysek","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib59","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib60","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/0269881114542454","article-title":"Differential effects of MDMA and methylphenidate on social cognition","volume":"28","author":"Schmid","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib61","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/npp.2013.125","article-title":"Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor","volume":"38","author":"Ramos","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","article-title":"Psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans","volume":"23","author":"Liechti","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib64","doi-asserted-by":"crossref","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","article-title":"Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study","volume":"7","author":"Hysek","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2014.11.015_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130000648","article-title":"Gender differences in the subjective effects of MDMA","volume":"154","author":"Liechti","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib66","doi-asserted-by":"crossref","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2014.11.015_bib67","first-page":"909","article-title":"Acute and chronic LSD effects on rat startle: Data supporting an LSD rat model of schizophrenia","volume":"15","author":"Braff","year":"1980","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib68","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.npp.1301324","article-title":"The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval","volume":"32","author":"Vollenweider","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib69","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00008877-199811000-00011","article-title":"Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans","volume":"9","author":"Gouzoulis-Mayfrank","year":"1998","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib70","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib71","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/0269881107077734","article-title":"Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis","volume":"21","author":"Heekeren","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonzalez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2014.11.015_bib73","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.biopsych.2009.05.007","article-title":"Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: A replication study","volume":"66","author":"Quednow","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1176\/ajp.114.4.309","article-title":"Relation of physiological and psychological effects of lysergic acid diethylamide","volume":"77","author":"Kornetsky","year":"1957","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1176\/ajp.114.4.309","article-title":"A study of the effects of L.S.D.: Physiologic and psychological changes and their interrelations","volume":"114","author":"Dimascio","year":"1957","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib76","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1749-6632.1957.tb40742.x","article-title":"The effects of D-lysergic acid diethylamide on cerebral circulation and over-all metabolism","volume":"66","author":"Sokoloff","year":"1957","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2014.11.015_bib77","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archneurpsyc.1956.02330290012002","article-title":"Studies on lysergic acid diethylamide (LSD-25): I. Effects in former morphine addicts and development of tolerance during chronic intoxication","volume":"76","author":"Belleville","year":"1956","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib78","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archneurpsyc.1951.02320050038004","article-title":"Experimental physiological studies with lysergic acid diethylamide (LSD-25)","volume":"65","author":"Forrer","year":"1951","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib79","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","article-title":"The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans","volume":"90","author":"Hysek","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2014.11.015_bib80","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1126\/science.120.3131.1100","article-title":"Pyretogenic effect of lysergic acid diethylamide","volume":"120","author":"Horita","year":"1954","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2014.11.015_bib81","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/15563657508988063","article-title":"Coma, hyperthermia, and bleeding associated with massive LSD overdose, a report of eight cases","volume":"8","author":"Klock","year":"1975","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","article-title":"Comparison of the reactions induced by psilocybin and LSD-25 in man","volume":"1","author":"Isbell","year":"1959","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.biopsych.2014.11.015_bib83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s002130050860","article-title":"Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers: Results of an experimental double blind placebo controlled study","volume":"142","author":"Gouzoulis-Mayfrank","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2014.11.015_bib85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02245940","article-title":"LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors","volume":"118","author":"Watts","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0024-3205(98)00262-8","article-title":"Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro","volume":"63","author":"Giacomelli","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2014.11.015_bib87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00426539","article-title":"Lysergic acid diethylamide: Evidence for stimulation of pituitary dopamine receptors","volume":"54","author":"Meltzer","year":"1977","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2014.11.015_bib88","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00191908","article-title":"Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine","volume":"46","author":"Sommers","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0893-133X(95)00117-V","article-title":"Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe","volume":"14","author":"Seifritz","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2014.11.015_bib90","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0378-8741(98)00168-8","article-title":"Pharmacokinetics of Hoasca alkaloids in healthy humans","volume":"65","author":"Callaway","year":"1999","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.biopsych.2014.11.015_bib91","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000364879","article-title":"Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects","volume":"100","author":"Seibert","year":"2014","journal-title":"Neuroendocrinology"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322314009093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322314009093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T19:34:08Z","timestamp":1566070448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322314009093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0006322314009093"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2014.11.015","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}